Sam Brusco, Associate Editor01.31.22
Glooko has acquired xbird, a Berlin-based health AI firm building just-in-time adaptive intervention (JITAI) tech for predicting behavior and managing diabetes.
xbird’s AI and machine learning tech interprets medical and behavioral data for customized recommendations and behavioral nudges. Smartphone and wearable sensors record movements and analyze the data to create personalized behavioral profiles and nudges to alter behavior and lifestyle decisions.
"We are thrilled to welcome the xbird team to the Glooko family,” Russ Johannesson, Glooko's CEO told the press. “Our investment in xbird represents Glooko's strategic commitment to machine learning and customized digital coaching for patients with chronic conditions. Among the many JITAI companies in the digital health landscape, xbird clearly has a superior solution, and has built successful partnerships throughout diabetes device manufacturers and clinical institutions. The combination of Glooko's established global footprint and xbird's exciting JITAI capabilities will allow us to improve patient outcomes."
Sebastian Sujka, CEO and co-founder of xbird stated, "xbird and Glooko are a great fit. We share a commitment to providing solutions that address multiple chronic conditions, delivering measurable outcomes, and we have a common mission to broadly serve all patients in need. Our goal is to continue the design of digital health solutions for those living with these conditions and to make our capabilities accessible to as many patients as possible."
Sujka will join Glooko as the Managing Director of Glooko GmbH, along with all of the xbird staff.
Glooko intends to integrate xbird’s JITAI digital coaching software into its established platform already used daily by over 7,500 clinics worldwide with over a million users.
xbird’s AI and machine learning tech interprets medical and behavioral data for customized recommendations and behavioral nudges. Smartphone and wearable sensors record movements and analyze the data to create personalized behavioral profiles and nudges to alter behavior and lifestyle decisions.
"We are thrilled to welcome the xbird team to the Glooko family,” Russ Johannesson, Glooko's CEO told the press. “Our investment in xbird represents Glooko's strategic commitment to machine learning and customized digital coaching for patients with chronic conditions. Among the many JITAI companies in the digital health landscape, xbird clearly has a superior solution, and has built successful partnerships throughout diabetes device manufacturers and clinical institutions. The combination of Glooko's established global footprint and xbird's exciting JITAI capabilities will allow us to improve patient outcomes."
Sebastian Sujka, CEO and co-founder of xbird stated, "xbird and Glooko are a great fit. We share a commitment to providing solutions that address multiple chronic conditions, delivering measurable outcomes, and we have a common mission to broadly serve all patients in need. Our goal is to continue the design of digital health solutions for those living with these conditions and to make our capabilities accessible to as many patients as possible."
Sujka will join Glooko as the Managing Director of Glooko GmbH, along with all of the xbird staff.
Glooko intends to integrate xbird’s JITAI digital coaching software into its established platform already used daily by over 7,500 clinics worldwide with over a million users.